Pharmaceuticals & Therapeutics

A massive conditional loan from the Pentagon's investment arm aims to transform a Utah uranium mill into a cornerstone of America's critical minerals strategy.

As Lindsay Corp prepares its Q3 report, investors are watching how the firm balances weak farm sentiment against rising demand for water-saving tech.

As CFO Dave Denton departs for the consumer goods sector, Pfizer taps a 20-year veteran for the interim role, signaling continuity amid a crucial post-acquisition phase.

A Filipino student's award-winning bathroom design highlights a major market shift. LIXIL's American Standard is capitalizing on the multigenerational home trend.

With regulatory approval for its Covelya Group acquisition, Kraken Robotics is creating a subsea giant, set to redefine ocean exploration and defense.

Beyond a simple merger, Conrex Group's acquisition of Formweld Fitting signals a strategic shift toward creating a resilient, one-stop industrial giant.

Early trial data for a novel antibody-drug conjugate shows a 32% response rate in a hard-to-treat patient group, signaling a potential new front in precision oncology.

After three decades, a new class of therapy for a rare liver disease lands in Singapore, rewriting the rules of care by targeting patient suffering, not just lab results.

As Philip Morris International shuffles its top ranks, we look at the leaders tasked with realizing a controversial, yet lucrative, smoke-free future.

Iceland's Alvotech secured a crucial capital infusion. It's a high-stakes play to survive financial pressures and compete in the next wave of affordable medicine.

A new report projects the wellness market will hit $12.9T by 2031. This isn't just about yoga mats; it's a tech-fueled, Asia-led economic realignment.

A new power deal between Statkraft and Alcoa is more than a contract. It’s a deep look into a national strategy for securing industry in a volatile world.

As Destinus rolls out its 1,000th turbojet, a new era of European military self-sufficiency dawns, breaking a critical dependency in defense manufacturing.

Japan's century-old CALPIS drink is coming to India. It's a story not just of a new beverage, but of a strategic system designed to conquer a complex market.

A landmark Sino-Singaporean joint venture aims to tackle global water scarcity by merging advanced Chinese membrane tech with Singaporean market savvy.

As Oncoinvent accelerates its Phase 2 trial, a novel alpha-emitter therapy shows promise against a deadly cancer, signaling progress in radiopharmaceuticals.

South Korea's JNJ International is leveraging Automechanika Mexico to enter the lucrative Latin American aftermarket, a region ripe with aging vehicles.

URBANICA’s new Conference Chair isn't just furniture; it's a calculated move into the office's most neglected real estate—the collaborative space.

An Arkansas lab's $30 million settlement with the DOJ offers a rare look into 'lean lab' models and the fine line between business and patient care.

GSK and Spero Therapeutics have won FDA approval for Utebzi, the first oral carbapenem for complex UTIs, a move that could slash healthcare costs.